Contact
searchSearch
HMP Global

Multiple Sclerosis Topic Center

Featured Article

News
Patient-Reported Outcomes Drive Value-Based Care in Multiple Sclerosis
01/13/2025
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in...
01/13/2025
First Report Managed Care
News
Study Suggests Cognitive Impairment More Likely With Late-Onset Multiple Sclerosis
12/19/2024
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset...
12/19/2024
First Report Managed Care
News
Meta-Analysis Finds More Arterial Stiffness in Patients With MS
12/13/2024
Patients with multiple sclerosis (MS) have significantly worse vascular function, particularly greater arterial stiffness, compared with healthy controls.
Patients with multiple sclerosis (MS) have significantly worse vascular function, particularly greater arterial stiffness, compared with healthy controls.
Patients with multiple sclerosis...
12/13/2024
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care
News
Transcriptional Signatures of Multiple Sclerosis May Explain Female-Biased Gene Expression
10/29/2024
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the...
10/29/2024
First Report Managed Care
News
Data on Black/African American and Hispanic/Latino Patients With Relapsing Multiple Sclerosis Receiving Ocrelizumab: CHIMES Trial 
10/28/2024
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the...
10/28/2024
First Report Managed Care
News
Risk of Disease Activity After Discontinuation of Disease-Modifying Drugs for Multiple Sclerosis
10/25/2024
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of...
10/25/2024
First Report Managed Care
News
Subcutaneous Ocrelizumab Shows Noninferiority to Intravenous Administration in Multiple Sclerosis Treatment
10/25/2024
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study...
10/25/2024
First Report Managed Care
News
COVID-19 Vaccination Does Not Increase Relapse Risk in Patients With Multiple Sclerosis
09/19/2024
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not...
09/19/2024
First Report Managed Care
News
The Role of BDNF in MS Remains Ambiguous
08/16/2024
Current evidence regarding the role of brain-derived neurotrophic factor (BDNF) in patients with multiple sclerosis (MS) is largely inconclusive, according to a review article published in Frontiers in Neurology.
Current evidence regarding the role of brain-derived neurotrophic factor (BDNF) in patients with multiple sclerosis (MS) is largely inconclusive, according to a review article published in Frontiers in Neurology.
Current evidence regarding the...
08/16/2024
First Report Managed Care

Newsfeed

News
Patient-Reported Outcomes Drive Value-Based Care in Multiple Sclerosis
01/13/2025
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in...
01/13/2025
First Report Managed Care
News
Study Suggests Cognitive Impairment More Likely With Late-Onset Multiple Sclerosis
12/19/2024
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset...
12/19/2024
First Report Managed Care
News
Meta-Analysis Finds More Arterial Stiffness in Patients With MS
12/13/2024
Patients with multiple sclerosis (MS) have significantly worse vascular function, particularly greater arterial stiffness, compared with healthy controls.
Patients with multiple sclerosis (MS) have significantly worse vascular function, particularly greater arterial stiffness, compared with healthy controls.
Patients with multiple sclerosis...
12/13/2024
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care
News
Transcriptional Signatures of Multiple Sclerosis May Explain Female-Biased Gene Expression
10/29/2024
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the...
10/29/2024
First Report Managed Care
News
Data on Black/African American and Hispanic/Latino Patients With Relapsing Multiple Sclerosis Receiving Ocrelizumab: CHIMES Trial 
10/28/2024
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the...
10/28/2024
First Report Managed Care
News
Risk of Disease Activity After Discontinuation of Disease-Modifying Drugs for Multiple Sclerosis
10/25/2024
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of...
10/25/2024
First Report Managed Care
News
Subcutaneous Ocrelizumab Shows Noninferiority to Intravenous Administration in Multiple Sclerosis Treatment
10/25/2024
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study...
10/25/2024
First Report Managed Care
News
COVID-19 Vaccination Does Not Increase Relapse Risk in Patients With Multiple Sclerosis
09/19/2024
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not...
09/19/2024
First Report Managed Care
News
Patient-Reported Outcomes Drive Value-Based Care in Multiple Sclerosis
01/13/2025
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in...
01/13/2025
First Report Managed Care
News
Study Highlights the Substantial Economic and Health Care Burden of Vitiligo
01/13/2025
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US...
01/13/2025
First Report Managed Care
News
Biosimilars Expand Access and Cut Costs in HER2-Positive Cancer Treatment
01/10/2025
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of...
01/10/2025
First Report Managed Care
News
COVID-19 Infection Linked to Increased Risk of Skin Conditions
01/08/2025
A recent study found that COVID-19 infection significantly increases the risk of developing skin conditions such as vitiligo, chronic urticaria, alopecia areata, and herpes zoster.
A recent study found that COVID-19 infection significantly increases the risk of developing skin conditions such as vitiligo, chronic urticaria, alopecia areata, and herpes zoster.
A recent study found that...
01/08/2025
First Report Managed Care
News
Provider Perceptions of Biosimilar Use in Oncology Networks
01/03/2025
Research published in the Journal of the American Pharmacists Association examined provider perceptions of barriers to biosimilar use in a large oncology network, revealing low levels of perceived barriers and high utilization rates, with...
Research published in the Journal of the American Pharmacists Association examined provider perceptions of barriers to biosimilar use in a large oncology network, revealing low levels of perceived barriers and high utilization rates, with...
Research published in the...
01/03/2025
First Report Managed Care
News
Study Suggests Cognitive Impairment More Likely With Late-Onset Multiple Sclerosis
12/19/2024
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset...
12/19/2024
First Report Managed Care
News
Evaluating Long-Term Cost Benefits of Etranacogene Dezaparvovec in Hemophilia B Management
12/19/2024
A study published in Journal of Managed Care and Specialty Pharmacy evaluated the budgetary implications of introducing etranacogene dezaparvovec, a novel gene therapy for hemophilia B, into a US commercial health plan.
A study published in Journal of Managed Care and Specialty Pharmacy evaluated the budgetary implications of introducing etranacogene dezaparvovec, a novel gene therapy for hemophilia B, into a US commercial health plan.
A study published in Journal of...
12/19/2024
First Report Managed Care
News
Financial Hardships Associated With Long COVID Across Income and Education Levels
12/19/2024
A study published in Health Services Research analyzing data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) has revealed a significant association between long COVID and financial hardships.
A study published in Health Services Research analyzing data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) has revealed a significant association between long COVID and financial hardships.
A study published in Health...
12/19/2024
First Report Managed Care
News
Oncology Biosimilars Offer Cost-Efficient Solutions for Sustainable Health Care
12/19/2024
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have...
12/19/2024
First Report Managed Care
News
Global Oncology Biosimilars Market to Surge to $35.79 Billion by 2034
12/19/2024
The global oncology biosimilars market is set to experience remarkable growth, with its value projected to soar from $6.50 billion in 2024 to $35.79 billion by 2034, at an impressive CAGR of 18.6%.
The global oncology biosimilars market is set to experience remarkable growth, with its value projected to soar from $6.50 billion in 2024 to $35.79 billion by 2034, at an impressive CAGR of 18.6%.
The global oncology biosimilars...
12/19/2024
First Report Managed Care
FRMC Volume 21, Issue 4

Current Issue

October/November/December Volume 21, Issue 4, First Report Managed Care
Current Issue
Issue Archive

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use